• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

磷酸乙醇胺复合C反应蛋白:一种能与人血清中天然低密度脂蛋白结合的类药物大分子。

Phosphoethanolamine-complexed C-reactive protein: a pharmacological-like macromolecule that binds to native low-density lipoprotein in human serum.

作者信息

Singh Sanjay K, Suresh Madathilparambil V, Prayther Deborah C, Moorman Jonathan P, Rusiñol Antonio E, Agrawal Alok

机构信息

Department of Pharmacology, James H. Quillen College of Medicine, East Tennessee State University, Johnson City, TN 37614, USA.

出版信息

Clin Chim Acta. 2008 Aug;394(1-2):94-8. doi: 10.1016/j.cca.2008.04.015. Epub 2008 Apr 27.

DOI:10.1016/j.cca.2008.04.015
PMID:18486609
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2491905/
Abstract

BACKGROUND

C-reactive protein (CRP) is an acute phase plasma protein. An important binding specificity of CRP is for the modified forms of low-density lipoprotein (LDL) in which the phosphocholine-binding sites of CRP participate. CRP, however, does not bind to native LDL.

METHODS

We investigated the interaction of CRP with native LDL using sucrose density gradient ultracentrifugation.

RESULTS

We found that the blocking of the phosphocholine-binding sites of CRP with phosphoethanolamine (PEt) converted CRP into a potent molecule for binding to native LDL. In the presence of PEt, CRP acquired the ability to bind to fluid-phase purified native LDL. Because purified native LDL may undergo subtle modifications, we also used whole human serum as the source of native LDL. In the presence of PEt, CRP bound to native LDL in serum also. The effect of PEt on CRP was selective for LDL because PEt-complexed CRP did not bind to high-density lipoprotein in the serum.

CONCLUSIONS

The pharmacologic intervention of endogenous CRP by PEt-based compounds, or the use of exogenously prepared CRP-PEt complexes, may turn out to be an effective approach to capture native LDL cholesterol in vivo to prevent the development of atherosclerosis.

摘要

背景

C反应蛋白(CRP)是一种急性期血浆蛋白。CRP的一个重要结合特异性是针对低密度脂蛋白(LDL)的修饰形式,其中CRP的磷酸胆碱结合位点参与其中。然而,CRP不与天然LDL结合。

方法

我们使用蔗糖密度梯度超速离心法研究了CRP与天然LDL的相互作用。

结果

我们发现用磷酸乙醇胺(PEt)阻断CRP的磷酸胆碱结合位点可将CRP转化为一种能与天然LDL结合的有效分子。在PEt存在的情况下,CRP获得了与液相纯化的天然LDL结合的能力。由于纯化的天然LDL可能会发生细微修饰,我们还使用全人血清作为天然LDL的来源。在PEt存在的情况下,CRP也能与血清中的天然LDL结合。PEt对CRP的作用对LDL具有选择性,因为PEt复合的CRP不与血清中的高密度脂蛋白结合。

结论

基于PEt的化合物对内源性CRP的药理干预,或使用外源性制备的CRP-PEt复合物,可能会成为一种在体内捕获天然LDL胆固醇以预防动脉粥样硬化发展的有效方法。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f34a/2491905/9db6fcfea407/nihms57041f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f34a/2491905/f53d41d2875f/nihms57041f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f34a/2491905/f92cfcfd10d4/nihms57041f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f34a/2491905/024a548451b4/nihms57041f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f34a/2491905/9db6fcfea407/nihms57041f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f34a/2491905/f53d41d2875f/nihms57041f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f34a/2491905/f92cfcfd10d4/nihms57041f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f34a/2491905/024a548451b4/nihms57041f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f34a/2491905/9db6fcfea407/nihms57041f4.jpg

相似文献

1
Phosphoethanolamine-complexed C-reactive protein: a pharmacological-like macromolecule that binds to native low-density lipoprotein in human serum.磷酸乙醇胺复合C反应蛋白:一种能与人血清中天然低密度脂蛋白结合的类药物大分子。
Clin Chim Acta. 2008 Aug;394(1-2):94-8. doi: 10.1016/j.cca.2008.04.015. Epub 2008 Apr 27.
2
C-reactive protein-bound enzymatically modified low-density lipoprotein does not transform macrophages into foam cells.与C反应蛋白结合的酶促修饰低密度脂蛋白不会将巨噬细胞转化为泡沫细胞。
J Immunol. 2008 Mar 15;180(6):4316-22. doi: 10.4049/jimmunol.180.6.4316.
3
Binding of the monomeric form of C-reactive protein to enzymatically-modified low-density lipoprotein: effects of phosphoethanolamine.C反应蛋白单体形式与酶修饰低密度脂蛋白的结合:磷酸乙醇胺的作用
Clin Chim Acta. 2009 Aug;406(1-2):151-5. doi: 10.1016/j.cca.2009.06.018. Epub 2009 Jun 21.
4
C-reactive protein binds to the 3beta-OH group of cholesterol in LDL particles.C反应蛋白与低密度脂蛋白颗粒中胆固醇的3β-羟基结合。
Biochem Biophys Res Commun. 2005 Apr 22;329(4):1208-16. doi: 10.1016/j.bbrc.2005.02.091.
5
Conformationally Altered C-Reactive Protein Capable of Binding to Atherogenic Lipoproteins Reduces Atherosclerosis.构象改变的 C 反应蛋白能够与动脉粥样硬化脂质结合,从而减少动脉粥样硬化。
Front Immunol. 2020 Aug 11;11:1780. doi: 10.3389/fimmu.2020.01780. eCollection 2020.
6
Rabbit and rat C-reactive proteins bind apolipoprotein B-containing lipoproteins.兔和大鼠的C反应蛋白与含载脂蛋白B的脂蛋白结合。
J Exp Med. 1984 Feb 1;159(2):604-16. doi: 10.1084/jem.159.2.604.
7
Functionality of C-Reactive Protein for Atheroprotection.C-反应蛋白的抗动脉粥样硬化功能。
Front Immunol. 2019 Jul 16;10:1655. doi: 10.3389/fimmu.2019.01655. eCollection 2019.
8
Comparative effects of 10-mg versus 80-mg Atorvastatin on high-sensitivity C-reactive protein in patients with stable coronary artery disease: results of the CAP (Comparative Atorvastatin Pleiotropic effects) study.10毫克与80毫克阿托伐他汀对稳定型冠状动脉疾病患者高敏C反应蛋白的比较效应:CAP(阿托伐他汀多效性比较)研究结果
Clin Ther. 2008 Dec;30(12):2298-313. doi: 10.1016/j.clinthera.2008.12.023.
9
Age, abdominal obesity, and baseline high-sensitivity C-reactive protein are associated with low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B responses to ezetimibe/simvastatin and atorvastatin in patients with metabolic syndrome.年龄、腹型肥胖和基线高敏 C 反应蛋白与代谢综合征患者接受依折麦布/辛伐他汀和阿托伐他汀治疗后低密度脂蛋白胆固醇、非高密度脂蛋白胆固醇和载脂蛋白 B 的反应相关。
J Clin Lipidol. 2013 Jul-Aug;7(4):292-303. doi: 10.1016/j.jacl.2013.03.007. Epub 2013 Apr 3.
10
Association between the serum lipoprotein-associated phospholipase A level and acute coronary syndrome.血清脂蛋白相关磷脂酶 A 水平与急性冠状动脉综合征的关系。
Cardiovasc J Afr. 2023;34(5):273-277. doi: 10.5830/CVJA-2022-056. Epub 2023 Jan 11.

引用本文的文献

1
Hypotheses on Atherogenesis Triggering: Does the Infectious Nature of Atherosclerosis Development Have a Substruction?动脉粥样硬化形成触发假说:动脉粥样硬化发展的传染性本质是否有依据?
Cells. 2023 Feb 23;12(5):707. doi: 10.3390/cells12050707.
2
Therapeutic potential of phosphoethanolamine-bound C-reactive protein in atherosclerosis.磷酸乙醇胺结合型C反应蛋白在动脉粥样硬化中的治疗潜力
Future Lipidol. 2008 Dec;3(6). doi: 10.2217/17460875.3.6.599.
3
Membrane curvature recognition by C-reactive protein using lipoprotein mimics.利用脂蛋白模拟物,C反应蛋白对膜曲率的识别

本文引用的文献

1
C-reactive protein-bound enzymatically modified low-density lipoprotein does not transform macrophages into foam cells.与C反应蛋白结合的酶促修饰低密度脂蛋白不会将巨噬细胞转化为泡沫细胞。
J Immunol. 2008 Mar 15;180(6):4316-22. doi: 10.4049/jimmunol.180.6.4316.
2
The connection between C-reactive protein and atherosclerosis.C反应蛋白与动脉粥样硬化之间的联系。
Ann Med. 2008;40(2):110-20. doi: 10.1080/07853890701749225.
3
Human C-reactive protein slows atherosclerosis development in a mouse model with human-like hypercholesterolemia.
Soft Matter. 2012 Aug 14;8(30):7909-7918. doi: 10.1039/C2SM25779C.
4
Effects of vildagliptin versus sitagliptin, on cardiac function, heart rate variability and mitochondrial function in obese insulin-resistant rats.维格列汀与西他列汀对肥胖胰岛素抵抗大鼠心脏功能、心率变异性及线粒体功能的影响。
Br J Pharmacol. 2013 Jul;169(5):1048-57. doi: 10.1111/bph.12176.
5
Atherosclerosis-related functions of C-reactive protein.C反应蛋白与动脉粥样硬化相关的功能
Cardiovasc Hematol Disord Drug Targets. 2010 Dec 1;10(4):235-40. doi: 10.2174/187152910793743841.
6
The binding of C-reactive protein, in the presence of phosphoethanolamine, to low-density lipoproteins is due to phosphoethanolamine-generated acidic pH.在磷酸乙醇胺存在的情况下,C反应蛋白与低密度脂蛋白的结合是由于磷酸乙醇胺产生的酸性pH值所致。
Clin Chim Acta. 2009 Nov;409(1-2):143-4. doi: 10.1016/j.cca.2009.08.013. Epub 2009 Aug 28.
7
Binding of the monomeric form of C-reactive protein to enzymatically-modified low-density lipoprotein: effects of phosphoethanolamine.C反应蛋白单体形式与酶修饰低密度脂蛋白的结合:磷酸乙醇胺的作用
Clin Chim Acta. 2009 Aug;406(1-2):151-5. doi: 10.1016/j.cca.2009.06.018. Epub 2009 Jun 21.
人C反应蛋白可减缓具有类人高胆固醇血症的小鼠模型中动脉粥样硬化的发展。
Proc Natl Acad Sci U S A. 2007 Aug 21;104(34):13768-73. doi: 10.1073/pnas.0706027104. Epub 2007 Aug 16.
4
Pathogenic implications for autoantibodies against C-reactive protein and other acute phase proteins.抗C反应蛋白及其他急性期蛋白自身抗体的致病意义
Clin Chim Acta. 2007 Mar;378(1-2):13-23. doi: 10.1016/j.cca.2006.12.002. Epub 2006 Dec 13.
5
Human C-reactive protein protects mice from Streptococcus pneumoniae infection without binding to pneumococcal C-polysaccharide.人C反应蛋白可保护小鼠免受肺炎链球菌感染,且不与肺炎球菌C多糖结合。
J Immunol. 2007 Jan 15;178(2):1158-1163. doi: 10.4049/jimmunol.178.2.1158.
6
Statins and biomarkers of inflammation.他汀类药物与炎症生物标志物
Curr Atheroscler Rep. 2007 Jan;9(1):33-41. doi: 10.1007/BF02693938.
7
C-reactive protein inhibits in vitro oxidation of low-density lipoprotein.C反应蛋白抑制低密度脂蛋白的体外氧化。
FEBS Lett. 2006 Oct 2;580(22):5155-60. doi: 10.1016/j.febslet.2006.08.045. Epub 2006 Sep 1.
8
Modified low density lipoproteins differentially bind and activate the C1 complex of complement.修饰的低密度脂蛋白以不同方式结合并激活补体C1复合物。
Mol Immunol. 2007 Feb;44(6):1169-77. doi: 10.1016/j.molimm.2006.06.013. Epub 2006 Aug 30.
9
Targeting C-reactive protein for the treatment of cardiovascular disease.以C反应蛋白为靶点治疗心血管疾病。
Nature. 2006 Apr 27;440(7088):1217-21. doi: 10.1038/nature04672.
10
Biomedicine. Lowering LDL--not only how low, but how long?生物医学。降低低密度脂蛋白——不仅要降得多低,还要降多久?
Science. 2006 Mar 24;311(5768):1721-3. doi: 10.1126/science.1125884.